Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2006 4
2007 1
2009 2
2010 1
2011 1
2012 2
2013 1
2014 2
2016 1
2020 2
2021 3
2022 1
2023 1
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
Mandl A, Jasmine S, Krueger T, Kumar R, Coleman IM, Dalrymple SL, Antony L, Rosen DM, Jing Y, Hanratty B, Patel RA, Jin-Yih L, Dias J, Celatka CA, Tapper AE, Kleppe M, Kanayama M, Speranzini V, Wang YZ, Luo J, Corey E, Sena LA, Casero RA, Lotan T, Trock BJ, Kachhap SK, Denmeade SR, Carducci MA, Mattevi A, Haffner MC, Nelson PS, Rienhoff HY, Isaacs JT, Brennen WN. Mandl A, et al. Among authors: dalrymple sl. bioRxiv [Preprint]. 2024 Jan 22:2024.01.17.576106. doi: 10.1101/2024.01.17.576106. bioRxiv. 2024. PMID: 38328141 Free PMC article. Preprint.
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
Jasmine S, Mandl A, Krueger TEG, Dalrymple SL, Antony L, Dias J, Celatka CA, Tapper AE, Kleppe M, Kanayama M, Jing Y, Speranzini V, Wang YZ, Luo J, Trock BJ, Denmeade SR, Carducci MA, Mattevi A, Rienhoff HY Jr, Isaacs JT, Brennen WN. Jasmine S, et al. Among authors: dalrymple sl. Prostate. 2024 Jul;84(10):909-921. doi: 10.1002/pros.24707. Epub 2024 Apr 15. Prostate. 2024. PMID: 38619005 Free PMC article.
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC.
Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, Skaist A, Yegnasubramanian S, Luo J, Brennen WN, Kachhap SK, Antonarakis ES, De Marzo AM, Isaacs JT, Markowski MC, Denmeade SR. Sena LA, et al. Among authors: dalrymple sl. J Clin Invest. 2022 Dec 1;132(23):e162396. doi: 10.1172/JCI162396. J Clin Invest. 2022. PMID: 36194476 Free PMC article.
Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, Yegnasubramanian S, Haffner MC, Nelson PS, Nelson WG, Isaacs WB, Isaacs JT. Brennen WN, et al. Among authors: dalrymple sl. JCI Insight. 2021 Apr 22;6(8):e146827. doi: 10.1172/jci.insight.146827. JCI Insight. 2021. PMID: 33724955 Free PMC article.
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Zhu Y, et al. Among authors: dalrymple sl. Oncogene. 2020 Nov;39(45):6935-6949. doi: 10.1038/s41388-020-01479-6. Epub 2020 Sep 28. Oncogene. 2020. PMID: 32989253 Free PMC article.
Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
Isaacs JT, Dalrymple SL, Antony L, Marc Rosen D, Coleman IM, Nelson PS, Kostova M, Murray IA, Perdew GH, Denmeade SR, Akinboye ES, Brennen WN. Isaacs JT, et al. Among authors: dalrymple sl. Prostate. 2023 Nov;83(15):1470-1493. doi: 10.1002/pros.24606. Epub 2023 Aug 9. Prostate. 2023. PMID: 37559436 Free PMC article.
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer.
Kumar R, Jonnatan S, Sanin DE, Vakkala V, Kadam A, Kumar S, Dalrymple SL, Zhao L, Foley J, Holbert CE, Nwafor A, Kittane S, Penner E, Apostolova P, Warner S, Dang CV, Toska E, Thompson EA, Isaacs JT, De Marzo AM, Pearce EL, Stewart TM, Casero RA, Denmeade SR, Sena LA. Kumar R, et al. Among authors: dalrymple sl. medRxiv [Preprint]. 2024 Dec 13:2024.12.12.24318845. doi: 10.1101/2024.12.12.24318845. medRxiv. 2024. PMID: 39711733 Free PMC article. Preprint.
Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Zhu Y, et al. Among authors: dalrymple sl. Oncogene. 2021 Jun;40(22):3914-3916. doi: 10.1038/s41388-021-01805-6. Oncogene. 2021. PMID: 33958727 No abstract available.
Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Zhu Y, et al. Among authors: dalrymple sl. Oncogene. 2021 Mar;40(11):2148. doi: 10.1038/s41388-021-01640-9. Oncogene. 2021. PMID: 33564077 No abstract available.
25 results